Literature DB >> 9258628

Adverse effects of class I antiarrhythmic drugs.

J Caron1, C Libersa.   

Abstract

Class I antiarrhythmic drugs are characterised by their ability to block the fast inward sodium current in cardiac muscle tissue. However, at the same time, they can be responsible for various effects involving other organs and systems. Although some of these effects can be helpful in specific situations, most of them, such as their pro-arrhythmic propensity, are deleterious. Some of the adverse effects of class I antiarrhythmic drugs are directly linked to sodium-channel blockade (conduction disorders haemodynamic perturbations, and digestive and neurological effects), while others are linked to other specific pharmacological properties (e.g. atropinic, or alpha- or beta-adrenergic blockade) or to nonspecific properties (idiosyncratic hypersensitivity, and haematological, dermatological or hepatic reactions). Other adverse effects are associated with complex interactions between class I antiarrhythmics and individual predisposing factors, trigger mechanisms and physiological factors (including concomitant drug treatment). These numerous variations and interactions within a specific environment and underlying disorder might be of pharmacological or/and pharmacokinetic origin, making analysis of the true liability of the class I drugs very difficult when adverse effects occur.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258628     DOI: 10.2165/00002018-199717010-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  329 in total

1.  Quinidine therapy of chronic auricular fibrillation. The occurrence and mechanism of syncope.

Authors:  R ROKSETH; O STORSTEIN
Journal:  Arch Intern Med       Date:  1963-02

Review 2.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 3.  Pill-induced esophageal strictures: clinical features and risk factors for development.

Authors:  G S McCord; R E Clouse
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

4.  Synovial fluid characteristics and the lupus erythematosus cell phenomenon in drug-induced lupus. Findings in three patients and review of pertinent literature.

Authors:  F B Vivino; H R Schumacher
Journal:  Arthritis Rheum       Date:  1989-05

5.  Cardiac effect of halofantrine.

Authors:  J Karbwang; K Na Bangchang; D Bunnag; T Harinasuta; P Laothavorn
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

6.  Comparative electrophysiological effects of propafenone, 5-hydroxy-propafenone, and N-depropylpropafenone on guinea pig ventricular muscle fibers.

Authors:  R Rouet; C C Libersa; F Broly; J F Caron; M M Adamantidis; E Honore; A Wajman; B A Dupuis
Journal:  J Cardiovasc Pharmacol       Date:  1989-10       Impact factor: 3.105

7.  Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias.

Authors:  S G Kim; S W Seiden; J A Matos; L E Waspe; J D Fisher
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

8.  Confusion and paranoia associated with oral tocainide.

Authors:  C W Clarke; E O el-Mahdi
Journal:  Postgrad Med J       Date:  1985-01       Impact factor: 2.401

Review 9.  Aggravation of arrhythmia: a complication of antiarrhythmic drugs.

Authors:  P J Podrid
Journal:  J Cardiovasc Electrophysiol       Date:  1993-06

10.  European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.

Authors:  P Coumel; J F Leclercq; P Assayag
Journal:  Am J Cardiol       Date:  1984-11-14       Impact factor: 2.778

View more
  5 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium.

Authors:  Herbert Plass; Markus Charisius; Wolfgang Wyskovsky; Florian Amor; Klaus Turnheim; Hubert Wiener
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

3.  NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

Authors:  J P Johnson; Thilo Focken; Kuldip Khakh; Parisa Karimi Tari; Celine Dube; Samuel J Goodchild; Jean-Christophe Andrez; Girish Bankar; David Bogucki; Kristen Burford; Elaine Chang; Sultan Chowdhury; Richard Dean; Gina de Boer; Shannon Decker; Christoph Dehnhardt; Mandy Feng; Wei Gong; Michael Grimwood; Abid Hasan; Angela Hussainkhel; Qi Jia; Stephanie Lee; Jenny Li; Sophia Lin; Andrea Lindgren; Verner Lofstrand; Janette Mezeyova; Rostam Namdari; Karen Nelkenbrecher; Noah Gregory Shuart; Luis Sojo; Shaoyi Sun; Matthew Taron; Matthew Waldbrook; Diana Weeratunge; Steven Wesolowski; Aaron Williams; Michael Wilson; Zhiwei Xie; Rhena Yoo; Clint Young; Alla Zenova; Wei Zhang; Alison J Cutts; Robin P Sherrington; Simon N Pimstone; Raymond Winquist; Charles J Cohen; James R Empfield
Journal:  Elife       Date:  2022-03-02       Impact factor: 8.140

Review 4.  Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.

Authors:  Sarah Rouhana; Anne Virsolvy; Nassim Fares; Sylvain Richard; Jérôme Thireau
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-25

5.  Mechanisms of flecainide induced negative inotropy: An in silico study.

Authors:  Pei-Chi Yang; Wayne R Giles; Luiz Belardinelli; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2021-05-15       Impact factor: 5.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.